Related references
Note: Only part of the references are listed.Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil
Peter Matzneller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
Philip D. Worboys et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Successful Target Attainment of Telavancin at Elevated MICs: Fact or Fiction?
Andras Farkas
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal Function
T. P. Lodise et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Telavancin versus Vancomycin for HospitalAcquired Pneumonia due to Gram-positive Pathogens
Ethan Rubinstein et al.
CLINICAL INFECTIOUS DISEASES (2011)
Recent advances in clinical microdialysis
Peter Matzneller et al.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY (2011)
New Lipoglycopeptides A Comparative Review of Dalbavancin, Oritavancin and Telavancin
George G. Zhanel et al.
DRUGS (2010)
Telavancin: A Novel Lipoglycopeptide Antibiotic
Lisa Charneski et al.
ANNALS OF PHARMACOTHERAPY (2009)
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms
Martin E. Stryjewski et al.
CLINICAL INFECTIOUS DISEASES (2008)
Dalbavancin and telavancin:: novel lipoglycopeptides for the treatment of Gram-positive infections
George G. Zhanel et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2008)
Tissue concentrations: do we ever learn?
Johan W. Mouton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
AAPS-FDA workshop white paper:: Microdialysis principles, application, and regulatory perspectives
Chandra S. Chaurasia et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections
Richard H. Drew
PHARMACOTHERAPY (2007)
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria:: FAST 2 study
ME Stryjewski et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Tissue penetration of telavancin after intravenous administration in healthy subjects
HK Sun et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution
Martin Brunner et al.
AAPS JOURNAL (2006)
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria
ME Stryjewski et al.
CLINICAL INFECTIOUS DISEASES (2005)
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria
SS Hegde et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS
BK Matuszewski et al.
ANALYTICAL CHEMISTRY (2003)
Science, medicine, and the future -: Microdialysis
M Müller
BMJ-BRITISH MEDICAL JOURNAL (2002)
Share Paper
